Microplate screening for apoptosis with antibody to single-stranded DNA distinguishes anticancer drugs from toxic chemicals

Journal of Biomolecular Screening

Volumn 8, Issue 2, 2003, Pages 185-190

  Frankfurt, Oskar S ^a,b   Krishan, Awtar ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Apostain Inc   (United States)

Author keywords

Apoptosis; Drug screening; Microplates; Single stranded DNA

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SINGLE STRANDED DNA; TETRAZOLIUM; TOXIC SUBSTANCE; ETOPOSIDE; TOXIN;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LEUKEMIA CELL; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; EVALUATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTIBODIES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DNA, SINGLE-STRANDED; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; HUMANS; TOXINS, BIOLOGICAL;

EID: 2142772631     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057103253326     Document Type: Article

References (25)

1. Wu GS, El-Deiry WS: Apoptotic death in tumor cells correlates with chemosensitivity, independent of p53 and bcl2. Clin Cancer Res 1996;2:623-633.
2. Sellers WR, Fisher D: Apoptosis and cancer drug targeting. J Clin Invest 1999;104:1655-1661.
3. Makin G, Hickman JA: Apoptosis and cancer chemotherapy. Cell Tissue Res 2000;301:143-152.
4. Milross CG, Mason KA, Hunter NR, et al: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-1314.
5. Caserrini CG, Pratesi M, Tortoreto B, et al: Apoptosis as a determinant of tumor sensitivity to topecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin Cancer Res 1997;3:955-961.
6. Symmans WF, Volm MD, Shapito ML, et al: Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000;6:4610-4617.
7. Frankfurt OS, Seckinger D, Sugarbaker EV: Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response. Int J Cancer 1994;59:217-224.
8. Fulda S, Wick W, Weller M, et al: Smac agonists sensitise for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant gliomas in vivo. Nature Med 2002;8:808-815.
9. Sheers EM, Ekwal B, Dierickx PJ: In vitro long-term cytotoxicity testing of 27 MEIC chemicals on HEP 2 cells and comparison with acute human toxicity data. Toxicol In Vitro 2001;15:153-161.
10. Evans SM, Casartelli A, Herreros E, et al: Development of high throughput toxicity screen predictive of high acute in vivo toxic potential. Toxicol In Vitro 2001;15:579-584.
11. Frankfurt OS, Seckinger D, Sugarbaker EV, et al: Monoclonal antibody to single-stranded DNA is a sensitive and specific cellular marker of apoptosis. Exp Cell Res 2001;226:387-397.
12. Frankfurt OS, Seckinger D, Sugarbaker EV, et al: Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl2 expression, hormone receptors and lymph node metastases. Clin Cancer Res 1997;3:465-471.
13. Frankfurt OS, Krishan A: Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J Histochem Cytochem 2001;49:369-378.
14. Mathiasen IS, Jaattela M: Triggering caspase-independent cell death to combat cancer. Trends Mol Med 2002;8:212-220.
15. Frankfurt OS, Krishan A: Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. J Immunol Methods 2001;253:133-144.
16. Johnson JL, Decker S, Zaharevitz D, et al: Relationship between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-1431.
17. Frankfurt OS: Decreased DNA stability in cells treated with alkylating agents. Exp Cell Res 1990;191:181-185.
18. Carmichael J, DeGraff WG, Gazdar AF, et al: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-942.
19. Slater K: Cytotoxicity tests for high-throughput drug discovery. Curr Opinion Biotechnol 2001;12:70-74.
20. Aldridge DR, Radford IR: Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res 1998;58:2817-2824.
21. Amundson SA, Myers TG, Scudiero D, et al: An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-6110.
22. Vousden KH: p53: Death star. Cell 2000;103:691-692.
23. Yin DX, Schimke RT: Bcl2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 1995;55:4922-4928.
24. Lock RB, Stribinskiene L: Dual mode of death induced by etoposide in human epithelial tumor cells allow bcl2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996;56:4006-4012.
25. Brown JM, Wouters BJ: Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-1399.